Nasdaq gains more than 1.4% in biggest rally of 2017

MYL

Recent Articles

Valeant Pharmaceuticals Intl Inc (VRX) Stock Isn’t Healed by Paulson’s Presence

Valeant Pharmaceuticals (VRX) finds relief as John Paulson joins the board, but what can he really do to help VRX stock holders? More 

Adamis Pharmaceuticals Corp (ADMP) Stock Up, Then Down on Allergy Med

Adamis Pharmaceuticals (ADMP) shares soared as the company unveiled a medication to treat allergies that serves as an EpiPen alternative. More 

Why Mylan N.V. (MYL), Cheesecake Factory Inc (CAKE) and Fossil Group Inc (FOSL) Are 3 of Today’s Worst Stocks

Mylan (MYL), Cheesecake Factory (CAKE) and Fossil Group (FOSL) couldn't win for losing on Tuesday. Here's what went wrong. More 

Teva Pharmaceutical Industries Ltd (ADR) (TEVA): Nibble on Its Dividend and Wait

Teva Pharmaceutical (TEVA) is perhaps the poster child for what can go wrong with an investment. But TEVA stock is cheap and could double in price. More 

How Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Could Recover

Teva Pharmaceutical desperately needs a new CEO - and a new strategy to boot - to stop the steady decline in TEVA stock. More 

Mylan NV (MYL) Ekes Out Q1 Earnings Beat Despite EpiPen Sales Decline

Drugmaker Mylan (MYL) got no help from EpiPen as it gave MYL stock holders a better-than-expected quarter. More 

“Haunted” Mylan N.V. (MYL) Stock Is Due for More Pain

Mylan (MYL) may have a nice track record of growth thanks to the EpiPen, but legal headwinds and general decency pose a significant threat to MYL stock. More